The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Open accessAbstract
BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in such women. METHODS: We conducted a prospective study of 139 women with a pathogenic BRCA1 or BRCA2 mutation who were enrolled in a breast-cancer surveillance program at the Rotterdam Family Cancer Clinic. At the time of enrollment, none of the women had a history of breast cancer. Seventy-six of these women eventually underwent prophylactic mastectomy, and the other 63 remained under regular surveillance. The effect of mastectomy on the incidence of breast cancer was analyzed by the Cox proportional-hazards method in which mastectomy was modeled as a time-dependent covariate. RESULTS: No cases of breast cancer were observed after prophylactic mastectomy after a mean (+/-SE) follow-up of 2.9+/-1.4 years, whereas eight breast cancers developed in women under regular surveillance after a mean follow-up of 3.0+/-1.5 years (P=0.003; hazard ratio, 0; 95 percent confidence interval, 0 to 0.36). The actuarial mean five-year incidence of breast cancer among all women in the surveillance group was 17+/-7 percent. On the basis of an exponential model, the yearly incidence of breast cancer in this group was 2.5 percent. The observed number of breast cancers in the surveillance group was consistent with the expected number (ratio of observed to expected cases, 1.2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies on PM consistently show a risk reduction of breast cancer of at least 90% [1,2]”
From Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy (2009) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which has been shown to reduce the incidence of breast cancer by approximately 90% [57-59]”
From Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of BRCA1 or BRCA2 Pathogenic Variants (2026) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,428
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Lerman, C., Narod, S., Schulman, K., Hughes, C., Gomez-Caminero, A., Bonney, G., Gold, K., Trock, B., Main, D., Lynch, J., et al. (1996) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.275.24.1885 · Cited by 840
BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer
Lerman, C. E. (1996) · JAMA · doi:10.1001/jama.1996.03530480027036 · Cited by 826
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670
Research works printed but not linked: 4
- Whittemore AS, 1997, Am J Hum Genet, 60, 496
- Hartmann LC, 2000, Proc Am Assoc Cancer Res, 41, 222
- Kriege M, 2000, Eur J Cancer, 36, S137
- Zion SM, 2000, Prog Proc Am Soc Clin Oncol, 19, 441a
Cited by
Sorted by citations
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H. L., Tilanus‐Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,686
“Posthysterectomy 3 (1) 48 (5) 24 (5) 75 (4)”
Self-citationDomchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
“Risk-reducing mastectomy is a highly effective strategy for breast cancer risk reduction.(20,21) In our prospec-”
Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M. L., Hudis, C. A., Ellis, N. A., Boyd, J. A., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,250
Kuhl, C. K., Schrading, S., Leutner, C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W. C., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,148
“BRCA2 mutations compared with so-called watchful waiting.(13-16) Nonetheless, the perceived mutilating effects of mastectomy make the decision for surgical prevention difficult, and current national guidelines do not recommend it as standard management.”
BackgroundDaly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A. M., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,143
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171
“In the only other study of BRCA1/2 mutation carriers to date, Meijers-Heijboer et al [6] reported no postbilateral prophylactic mastectomy breast cancers in 76 BRCA1/2 mutation carriers after 2.”
BackgroundResultInfluentialCancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2
King, M. (2001) · JAMA · doi:10.1001/jama.286.18.2251 · Cited by 776
“Over 3 years of follow-up, invasive breast cancer occurred in 8 of 63 women with inherited BRCA1 or BRCA2 mutations, who had opted for surveillance alone, but in none of 76 women who underwent prophylactic mastectomy.(37) Other data indicates that early prophylactic oophorectomy reduces the risk of subsequent breast c…”
BackgroundEfficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 721
Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
Walsh, T., Casadei, S., Coats, K. H., Swisher, E. M., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J. B., Lee, M. K., Čierniková, S., et al. (2006) · JAMA · doi:10.1001/jama.295.12.1379 · Cited by 673
“Clinical options for women at high genetic risk of breast cancer include screening starting at a young age,(19) the use of highly sensitive detection methods,(20) and prophylactic surgeries of the ovaries or breast.(21-27) Because prophylactic surgeries, while highly effective in reducing risk, are also highly invasiv…”
BackgroundGenetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S. S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature reviews. Immunology · doi:10.1038/nri1150 · Cited by 631
Wooster, R., & Weber, B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 619
The BOADICEA model of genetic susceptibility to breast and ovarian cancer
Antoniou, A. C., Pharoah, P. D. P., Smith, P., & Easton, D. F. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602175 · Cited by 473
Guidelines for Preventive Activities in General Practice
Ackermann, E. W., Harris, M., Alexander, K. L., Arcus, M., Bailey, L., Bennett, J. W., Mar, C. D., Emery, J. D., Ewald, B. D., Ewald, D. P., et al. (2012) · e-publications@bond (Bond University) · Cited by 421
U.S. Preventive Services Task Force* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00011 · Cited by 405
“…criteria) of prophylactic bilateral mastectomy in high-risk women show a consistent 85% to 100% reduction in risk for breast cancer despite differences in study designs and comparison groups (for example, sisters 42 , matched controls 43 , a surveillance group 44 , and penetrance models 45 .”
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1260 · Cited by 404
Prophylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., & Wallace, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub3 · Cited by 402
Paluch–Shimon, S., Cardoso, F., Sessa, C., Balmañà, J., Cardoso, M. J., Gilbert, F. J., & Senkus, E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw327 · Cited by 400
Lehman, C. D., Isaacs, C. J., Schnall, M. D., Pisano, E. D., Ascher, S. M., Weatherall, P. T., Bluemke, D. A., Bowen, D. J., Marcom, P. K., Armstrong, D. K., et al. (2007) · Radiology · doi:10.1148/radiol.2442060461 · Cited by 399
“2) [0, 4] 0/171 (0)”
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Narod, S., Dubé, M.-P., Klijn, J., Lubiński, J., Lynch, H., Ghadirian, P., Provencher, D., Heimdal, K., Møller, P., Robson, M., et al. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.23.1773 · Cited by 375
Genetic susceptibility to breast cancer
Mavaddat, N., Antoniou, A. C., Easton, D. F., & García‐Closas, M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.011 · Cited by 407
“…may be offered more personalized clin- ical management and receive prophylactic therapies such as oophorectomy or mastectomy; or aromatase inhibitors, in the case of ER-positive disease (Friebel et al., 2007; Hartmann et al., 2001; Meijers-Heijboer et al., 2001; Rebbeck et al., 2002, 2004, 2009b).”
BackgroundCurrent Status of Breast MR Imaging Part 2. Clinical Applications
Kuhl, C. K. (2007) · Radiology · doi:10.1148/radiol.2443051661 · Cited by 375
Nelson, H. D., Huffman, L. H., Fu, R. F., & Harris, E. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00012 · Cited by 345
“Results were consistent, indicating an 85% to 100% risk reduction for breast cancer despite differences in study designs and comparison groups that included sisters (161), matched controls (163), a surveillance group (127), and penetrance models (162).”
BackgroundResultPierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340
“Although the present results demonstrate a reduction in ipsilateral and contralateral breast cancer events associated with oophorectomy and tamoxifen use in BRCA1/2 carriers, the reductions are modest compared with the 90% or greater reductions observed after bilateral prophylactic mastectomy.(4-6) Given that a random…”
ResultMetcalfe, K. A., Birenbaum‐Carmeli, D., Lubiński, J., Gronwald, J., Lynch, H. T., Møller, P., Ghadirian, P., Foulkes, W. D., Klijn, J. G. M., Friedman, E., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23340 · Cited by 342
“also found a significant reduction in the risk of breast cancer associated with prophylactic mastectomy.(18)”
BackgroundSelf-citationPage, D. L., Schuyler, P. A., Dupont, W. D., Jensen, R. A., Plummer, W. D., & Simpson, J. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12230-1 · Cited by 334
PTEN hamartoma tumor syndromes
Blumenthal, G. M., & Dennis, P. A. (2008) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.162 · Cited by 337
Nipple-Sparing Mastectomy for Breast Cancer and Risk Reduction: Oncologic or Technical Problem?
Sacchini, V., Pinotti, J. A., de Barros, A. C. S. D., Luini, A., Pluchinotta, A. M., Pinotti, M., Boratto, M. G., Ricci, M. D., Ruiz, C. A., Nisida, A. C. T., et al. (2006) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.07.015 · Cited by 323
Risk-reducing mastectomy for the prevention of primary breast cancer
Carbine, N. E., Lostumbo, L., Wallace, J., & Ko, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub4 · Cited by 270
Herrinton, L. J., Barlow, W. E., Yu, O., Geiger, A. M., Elmore, J. G., Barton, M. B., Harris, E. L., Rolnick, S. J., Pardee, R., Husson, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.080 · Cited by 268
Brandberg, Y., Sandelin, K., Erikson, S., Jurell, G., Liljegren, A., Lindblom, A., Lindén, A., von Wachenfeldt, A., Wickman, M., & Arver, B. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9568 · Cited by 267
Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging
Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., Stockdale, F. E., & Garber, A. M. (2006) · JAMA · doi:10.1001/jama.295.20.2374 · Cited by 261
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
Hartmann, L. C., & Lindor, N. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1503523 · Cited by 254
LANCASTER, J., BETHANPOWELL, C., Kauff, N. D., Cass, I. A., CHEN, L., LU, K., Mutch, D. G., Berchuck, A., Karlan, B. Y., & Herzog, T. J. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.09.031 · Cited by 251
“[20–23].”
Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women
Nanda, R., Schumm, L. P., Cummings, S. A., Fackenthal, J. D., Sveen, L., Ademuyiwa, F. O., Cobleigh, M., Esserman, L. J., Lindor, N. M., Neuhausen, S. L., et al. (2005) · JAMA · doi:10.1001/jama.294.15.1925 · Cited by 250
“High-risk women are advised to begin intensive surveillance at either 10 years younger than the earliest case of breast cancer in the family or at age 25 years, consider riskreducing prophylactic surgery, and undergo screening magnetic resonance imaging of the breast.(1-4) An estimated 5% to 10% of breast cancer cases…”
BackgroundASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.
Guillem, J., Wood, W., Moley, J., Berchuck, A., Karlan, B., Mutch, D., Gagel, R., Weitzel, J., Morrow, M., Weber, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5260 · Cited by 124
“Although a randomized trial to address this subject in the purest fashion is not feasible, several studies have recently emerged comparing those mutation carriers who elected prophylactic bilateral mastectomy with those who did not.(20) Reassuringly, this also demonstrated a risk reduction of at least 90%.”
BackgroundOutcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Scheuer, L., Kauff, N. D., Robson, M. E., Kelly, B. N., Barakat, R. R., Satagopan, J. M., Ellis, N. A., Hensley, M. L., Boyd, J. A., Borgen, P. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1260 · Cited by 239
Li, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., Yu, B., Xu, T., Cai, H., & Zou, Q. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1465 · Cited by 234
Precision Medicine from a Public Health Perspective
Ramaswami, R., Bayer, R., & Galea, S. (2017) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040617-014158 · Cited by 243
BRCA in breast cancer: ESMO Clinical Practice Guidelines
Balmañà, J., Dı́ez, O., Rubio, I. T., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr373 · Cited by 230
Evans, D. G., Shenton, A., Woodward, E. R., Lalloo, F. I., Howell, A., & Maher, E. R. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-155 · Cited by 224
Friedreich ataxia: the oxidative stress paradox
Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Golik, P., Procaccio, V., Patel, M., Drapier, J.-C., Koenig, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi042 · Cited by 219
Bedrosian, I., Hu, C., & Chang, G. J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq018 · Cited by 217
BRCA in breast cancer: ESMO Clinical Practice Guidelines
Balmañà, J., Dı́ez, O., Rubio, I. T., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq161 · Cited by 205
Application of Breast Cancer Risk Prediction Models in Clinical Practice
Domchek, S. M., Eisen, A. F., Calzone, K., Stopfer, J. E., Blackwood, A. M., & Weber, B. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.007 · Cited by 201
Hereditary Breast and Ovarian Cancer
Meindl, A., Ditsch, N. C., Kast, K., Rhiem, K., & Schmutzler, R. K. (2011) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2011.0323 · Cited by 206
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
Heemskerk‐Gerritsen, B. A. M., Jager, A., Koppert, L. B., Obdeijn, A. I. M., Collee, M. J., Meijers-Heijboer, H. E. J., Jenner, D. J., Oldenburg, H. S. A., van Engelen, K., de Vries, J., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05345-2 · Cited by 200
Self-citationFrost, M. H., Slezak, J. M., Tran, N. V., Williams, C. I., Johnson, J. L., Woods, J. E., Petty, P. M., Donohue, J. H., Grant, C. S., Sloan, J. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.233 · Cited by 197
Botkin, J., Smith, K. R., Croyle, R. T., Baty, B. J., Wylie, J. E., Dutson, D., Chan, A., Hamann, H., Lerman, C., McDonald, J., et al. (2003) · American Journal of Medical Genetics. Part A · doi:10.1002/ajmg.a.10102 · Cited by 219
Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome
(2017) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002296 · Cited by 195
van der Kolk, D. M., de Bock, G. H., Leegte, B. K., Schaapveld, M., Mourits, M. J. E., de Vries, J., van der Hout, A. H., & Oosterwijk, J. C. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0805-3 · Cited by 187
“However, since ovarian cancer screening is not effective [3], women are advised to undergo a prophylactic bilateral salpingo oophorectomy (pBSO) after child-bearing age [4, 5].”
BackgroundHereditary breast and ovarian cancer: review and future perspectives
Lux, M. P., Fasching, P. A., & Beckmann, M. W. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0696-7 · Cited by 187
Rijnsburger, A. J., Obdeijn, I.-M., Kaas, R., Tilanus‐Linthorst, M. M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., Kok, T., Muller, S. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2294 · Cited by 183
“The risk of breast cancer can be reduced by prophylactic surgery or chemoprevention.(5-9) A promising strategy to reduce the risk of breast cancer death is early diagnosis by intensive surveillance.”
BackgroundSelf-citationMetcalfe, K. A., Eisen, A. F., Senter, L. A., Armel, S. R., Bordeleau, L. J., Meschino, W. S., Pal, T., Lynch, H. T., Tung, N., Kwong, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0446-1 · Cited by 180
Modifiers of risk of hereditary breast and ovarian cancer
Narod, S. A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc726 · Cited by 179
Disparities in Genetic Testing: Thinking Outside theBRCABox
Hall, M. J., & Olopade, O. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.5889 · Cited by 174
Breast cancer prevention in high-risk women
Thorat, M. A., & Balasubramanian, R. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.11.006 · Cited by 176
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations
Eleje, G. U., Eke, A. C., Ezebialu, I. U., Ikechebelu, J. I., Ugwu, E. O., & Okonkwo, O. O. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012464.pub2 · Cited by 172
Prevention and Management of Hereditary Breast Cancer
Narod, S. A., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.035 · Cited by 167
Kleinberg, D. L., Wood, T. L., Furth, P. A., & Lee, A. V. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0022 · Cited by 162
“often elect to have prophylactic bilateral mastectomies, which can drastically lower the development of breast cancer (257).”
BackgroundArmstrong, K., Schwartz, J. S., Randall, T. C., Rubin, S. C., & Weber, B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.090 · Cited by 161
“0 [43]”
Heemskerk-Gerritsen, B. A. M., Brekelmans, C. T. M., Menke-Pluymers, M. B. E., van Geel, A. N., Tilanus-Linthorst, M. M. A., Bartels, C. C. M., Tan, M., Meijers-Heijboer, H. E. J., Klijn, J. G. M., & Seynaeve, C. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9449-x · Cited by 153
“33 Necrosis 1 (1) 3 (5) Capsular formation 31 (37) 20 (35) Prosthesis luxation 2 (2) 3 (5) Poor cosmetic appearance d 31 (37) 19 (34) Dog ear 16 (19) 12 (21)”
Self-citationPretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Euhus, D., Smith, K. C., Robinson, L., Stucky, A., Olopade, O., Cummings, S., Garber, J., Chittenden, A., Mills, G., Rieger, P., et al. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.844 · Cited by 114
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan, J. M., Boyd, J. A., Kauff, N. D., Robson, M. E., Scheuer, L., Narod, S. A., & Offit, K. (2002) · PubMed · Cited by 152
Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation
Anderson, K. N., Jacobson, J. S., Heitjan, D. F., Zivin, J. G., Hershman, D. L., Neugut, A. I., & Grann, V. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-6-200603210-00006 · Cited by 151
“Other recent studies suggest that bilateral prophylactic mastectomy may reduce the risk for breast cancer by 90% (12, 21, 29), tamoxifen (taken for 5 years) may reduce the risk for breast cancer by 49% (25, 30), and oral contraceptives may reduce the risk for ovarian cancer by 54% (31, 32).”
Hoogerbrugge, N., Bult, P., de Widt-Levert, L. M., Beex, L. V. A. M., Kiemeney, L. A. L. M., Ligtenberg, M. J. L., Massuger, L., Boetes, C., Manders, P., & Brunner, H. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.137 · Cited by 149
Udagawa, T., Fernández, A., Achilles, E., Folkman, J., & D’Amato, R. J. (2002) · The FASEB Journal · doi:10.1096/fj.01-0813com · Cited by 147
“In vivo models for human tumor dormancy would also be useful in the design of therapies to treat occult cancers to prevent relapse or primary cancer, particularly in individuals who are at high risk (20, 21, 48).”
BackgroundCancer Prevention: From 1727 to Milestones of the Past 100 Years
Lippman, S. M., & Hawk, E. T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1750 · Cited by 151
“cohort studies demonstrated that prophylactic mastectomy in women at risk of familial breast cancer (186), including BRCA1 or BRCA2 mutation carriers (187), substantially reduced the risk of”
BackgroundEffect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis.
Weitzel, J., McCaffrey, S., Nedelcu, R., Macdonald, D., Blazer, K., & Cullinane, C. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.12.1323 · Cited by 172
Evans, D. G., Lalloo, F. I., Ashcroft, L., Shenton, A., Clancy, T., Baildam, A. D., Brain, A., Hopwood, P., & Howell, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0171 · Cited by 147
“The efficacy of surgical procedures for reducing the risk of breast and ovarian cancer is now beyond dispute (2-6).”
BackgroundThe development of interval breast malignancies in patients with BRCA mutations
Komenaka, I. K., Ditkoff, B., Joseph, K.-A. P., Russo, D., Gorroochurn, P., Ward, M., Horowitz, E., El-Tamer, M. B., & Schnabel, F. R. (2004) · Cancer · doi:10.1002/cncr.20221 · Cited by 147
“– 6 Nonetheless, in spite of the debate regarding survival benefit, widespread adoption of the published breast carcinoma screening guidelines has led to earlier detection of breast malignancies and to the detection of a larger proportion of these malignancies in a noninvasive stage.(6,7) Over the last decade, with th…”
BackgroundHether, H. J., Huang, G. C., Beck, V., Murphy, S. T., & Valente, T. W. (2008) · Journal of Health Communication · doi:10.1080/10810730802487471 · Cited by 144
“While the prevalence of these surgeries is largely unknown, some studies report that between 19% and 50% of mutation-positive women have chosen to undergo prophylactic mastectomy to manage their cancer risks (Lynch, Lynch, & Rubinstein, 2001; Meijers-Heijboer et al., 2001).”
BackgroundIllness perceptions and distress in women at increased risk of breast cancer
Rees, G., Fry, A. M., Cull, A., & Sutton, S. R. (2004) · Psychology and Health · doi:10.1080/08870440412331279764 · Cited by 142
“High risk women may be offered prophylactic bilateral mastectomy which has been found to be effective in reducing the incidence of breast cancer in BRCA1 or BRCA2 mutation carriers (Meijers-Heijboer et al., 2001).”
BackgroundAttitudes of Patients With Cancer About Personalized Medicine and Somatic Genetic Testing
Gray, S. W., Hicks-Courant, K., Lathan, C. S., Garraway, L., Park, E. R., & Weeks, J. C. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2012.000626 · Cited by 139
Risk factors and risk reduction of breast and ovarian cancer
Brekelmans, C. T. M. (2003) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200302000-00010 · Cited by 136
Self-citationYao, K. A., Liederbach, E., Tang, R., Lei, L., Czechura, T., Sisco, M., Howard, M. A., Hulick, P. J., Winchester, D. J., Coopey, S. B., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3883-3 · Cited by 130
“, there were no breast cancer cases in the prophylactic mastectomy group and eight cancers in the surveillance group at 3 years of follow-up.(15) Another study of 236 BRCA1/2 carriers showed no primary breast cancers at 4.”
Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy
Metcalfe, K., Esplen, M., Goel, V., & Narod, S. (2004) · Psycho-Oncology · doi:10.1002/pon.726 · Cited by 136
“For women who are at a very high risk of developing breast cancer, prophylactic mastectomy has been shown to reduce the risk of breast cancer by 80% or more (Hartmann et al., 1999, 2001; Meijers-Heijboer et al., 2001).”
BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Fu, X., Tan, W., Song, Q., Pei, H., & Li, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.813457 · Cited by 142
“RRM can reduce the risk of developing BC in BRCA1 carriers by more than 90% (Meijers-Heijboer et al., 2001; HeemskerkGerritsen et al., 2013; Li et al., 2016) and even reduce mortality from any cause (Honold and Camus, 2018).”
BackgroundShaag, A., Walsh, T., Renbaum, P., Kirchhoff, T., Nafa, K., Shiovitz, S., Mandell, J. B., Welcsh, P. L., Lee, M. K., Ellis, N. A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi052 · Cited by 129
Eisinger, F., Paillerets, B. B., Castaigne, D., Cottu, P. H., Lansac, J., Lefranc, J., Lesur, A., Noguès, C., Pierret, J., Puy‐Pernias, S., et al. (2006) · Pathologie Biologie · doi:10.1016/j.patbio.2006.02.002 · Cited by 150
Heemskerk‐Gerritsen, B. A. M., Menke‐Pluijmers, M. B. E., Jager, A., Tilanus‐Linthorst, M. M. A., Koppert, L. B., Obdeijn, I. M., van Deurzen, C. H. M., Collée, J. M., Seynaeve, C., & Hooning, M. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt134 · Cited by 123
“from our institute, reported reduction of BC risk after BRRM in healthy BRCA1 or BRCA2 mutation carriers [6–10].”
BackgroundResultSelf-citationProphylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., Wallace, J., Ezzo, J., & Dickersin, K. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub2 · Cited by 122
Meijers-Heijboer, H., Brekelmans, C., Menke-Pluymers, M., Seynaeve, C., Baalbergen, A., Burger, C., Crepin, E., van den Ouweland, A. V. D., van Geel, B. V., & Klijn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.052 · Cited by 150
Self-citationSkytte, A., Gerdes, A., Andersen, M., Sunde, L., Brøndum‐Nielsen, K., Waldstrøm, M., Kølvraa, S., & Crüger, D. G. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01329.x · Cited by 118
Razdan, S. N., Patel, V., Jewell, S., & McCarthy, C. M. (2015) · Quality of Life Research · doi:10.1007/s11136-015-1181-6 · Cited by 119
Recognition and Management of Hereditary Breast Cancer Syndromes
Thull, D. L., & Vogel, V. G. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-13 · Cited by 118
Satisfaction with Prophylactic Mastectomy and Breast Reconstruction in Genetically Predisposed Women
Bresser, P. J. C., Seynaeve, C., Gool, A. R. V., Brekelmans, C. T. M., Meijers-Heijboer, H. E. J., van Geel, A. N., Menke‐Pluijmers, M. B. E., Duivenvoorden, H. J., Klijn, J. G. M., & Tibben, A. (2006) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000217383.99038.f5 · Cited by 117
“Being satisfied with result of PM/BR 113 68 (60) 13 (12) 32 (28) Would opt for PM again 112 106 (95) 5 (5) 1 (1) Would opt for BR again 112 89 (80) 12 (11) 11 (10) Feeling sufficiently informed 112 95 (85) 1 (1) 16 (14) Surgery did not meet expectations 112 35 (31) 8 (7) 69 (62) Complications‡ 113 48 (43) 2 (2) 63 (56…”
InfluentialSelf-citationBRCA1 : mechanisms of inactivation and implications for management of patients
Kennedy, R. D., Quinn, J. E., Johnston, P. G., & Harkin, D. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11087-7 · Cited by 116
Modifiers of risk of hereditary breast cancer
Narod, S. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209870 · Cited by 116
“In a cohort of 76 BRCA1 mutation carriers from Rotterdam, eight invasive cancers were detected during 318 person-years of follow-up (Meijers-Heijboer et al., 2001) – an annual incidence of 2.”
BackgroundInfluentialSardanelli, F., & Podo, F. (2006) · European Radiology · doi:10.1007/s00330-006-0389-9 · Cited by 116
Wainberg, S., & Husted, J. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.1989.13.12 · Cited by 116
“Salt Lake City, UT, USA 26 In-person interview 12 months 24 months Ages 25-39 Ages >40 — 54% (14) 71% (12) 22% (2) — 46% (12) 29% (5) 78% (7)”
InfluentialFatouros, M., Baltoyiannis, G., & Roukos, D. H. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9612-4 · Cited by 115
“003) breast cancer incidence among the women who did not have the procedure.(35) Moreover, PBM reduced the risk of breast cancer by approximately 95% in women with previous or concurrent PBM and reduced the risk by approximately 90% in women with intact ovaries.”
BackgroundBreast Cancer Screening with MRI — What Are the Data for Patients at High Risk?
Liberman, L. (2004) · New England Journal of Medicine · doi:10.1056/nejme048117 · Cited by 114
Translational advances regarding hereditary breast cancer syndromes
Gage, M. M., Wattendorf, D. J., & Henry, L. R. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.21856 · Cited by 118
“[27], no cases of breast cancer were seen over 3 years in 76 women who had prophylactic bilateral total mastectomies, whereas 8 of 63 women undergoing regular surveillance developed breast cancer.”
BackgroundContralateral prophylactic mastectomy
Goldflam, K., Hunt, K. K., Gershenwald, J. E., Singletary, S. E., Mirza, N. Q., Kuerer, H. M., Babiera, G. V., Ames, F. C., Ross, M. I., Feig, B. W., et al. (2004) · Cancer · doi:10.1002/cncr.20617 · Cited by 111
“More recently, studies in women with known BRCA1 and BRCA2 mutations have also demonstrated significant risk reduction with BPM.17,18 It is noteworthy that even with close observation, some of the breast carcinomas that developed in the observation group were lymph node positive, and one patient eventually died of bre…”
BackgroundArmstrong, K., Weber, B., FitzGerald, G., Hershey, J. C., Pauly, M. V., Lemaire, J., Subramanian, K., & Asch, D. A. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20025 · Cited by 108
“As women in this group had an average breast cancer risk over 20%, genetic testing might have been able to identify women who would be most likely tobenefit from interventions to reducebreast cancer risk, such as prophylactic mastectomy and tamoxifen [Fisher et al., 1998; Meijers-Heijboer et al., 2001].”
Background
Metadata
- Authors
- Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., Brekelmans, C. T. M., & Klijn, J. G. M.
- Affiliations
- Erasmus MC (NL)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-07-19
- Volume
- 345
- Issue
- 3
- Pages
- 159-164
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2046809735
- Cited by
- 973
- References
- 33
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 14 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 30 · 2018: 21 · 2017: 37 · 2016: 42 · 2015: 28 · 2014: 34 · 2013: 29 · 2012: 42
- FWCI
- 35.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, bilateral prophylactic mastectomy, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, breast cancer incidence, breast cancer surveillance, genetic susceptibility to cancer
- MeSH terms
- Adult, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Neoplasm Proteins, Prospective Studies, Transcription Factors, Mastectomy, Simple, Proportional Hazards Models, Genes, BRCA1, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
